TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Wedbush lowered their FY2026 earnings per share (EPS) estimates for TScan Therapeutics in a note issued to investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.97) per share for the year, down from their previous estimate of ($0.96). Wedbush has a "Outperform" rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics' FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.94) EPS.
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.
Several other research firms have also recently weighed in on TCRX. Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday.
Check Out Our Latest Report on TCRX
TScan Therapeutics Stock Performance
NASDAQ TCRX traded down $0.12 during trading hours on Friday, hitting $2.90. The company's stock had a trading volume of 563,300 shares, compared to its average volume of 261,178. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The company has a market cap of $154.77 million, a P/E ratio of -2.85 and a beta of 0.79. The company's 50 day simple moving average is $4.87 and its two-hundred day simple moving average is $5.91. TScan Therapeutics has a 12 month low of $2.60 and a 12 month high of $9.69.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP bought a new position in shares of TScan Therapeutics in the second quarter worth about $70,000. SG Americas Securities LLC purchased a new position in TScan Therapeutics during the third quarter valued at $78,000. The Manufacturers Life Insurance Company bought a new stake in TScan Therapeutics in the 2nd quarter valued at $90,000. XTX Topco Ltd purchased a new stake in TScan Therapeutics in the 3rd quarter worth $112,000. Finally, MetLife Investment Management LLC boosted its holdings in shares of TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company's stock valued at $116,000 after purchasing an additional 13,164 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company's stock.
Insider Activity at TScan Therapeutics
In other news, Director Barbara Klencke purchased 5,000 shares of the stock in a transaction on Monday, September 23rd. The shares were acquired at an average price of $5.29 per share, with a total value of $26,450.00. Following the completion of the acquisition, the director now directly owns 45,000 shares of the company's stock, valued at $238,050. This trade represents a 12.50 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.76% of the stock is currently owned by company insiders.
About TScan Therapeutics
(
Get Free Report)
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
See Also
Before you consider TScan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.
While TScan Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
